Alarm at BMW! Sell-off at BioNTech! Desert Gold Undervalued!

Desert Gold Significantly Undervalued

While the gold price holds steady above USD 4,000 per ounce, attractive buying opportunities are emerging in gold stocks. This is because little has changed regarding the fundamental drivers of rising prices for the precious metal. Debt in industrialized nations is climbing to ever-new heights, geopolitical uncertainties persist, and central banks remain on the buying side. Added to this is the fact that the monetary policy leeway for sustainably high interest rates remains limited. In addition to these fundamental developments, another argument in favour of buying Desert Gold shares is that the coming months will be particularly exciting for the company.

Desert Gold is on the verge of producing gold on its own for the first time using a small gravity plant at the SMSZ project in Mali. With the start of production in the Barani East area, Desert Gold would take the decisive step from being purely an explorer to becoming a potential cash flow generator.

Launching production via a relatively small-scale operation is a prudent strategic approach. Instead of immediately developing a capital-intensive, large-scale project, Desert Gold can first gain practical experience in mining, processing, logistics, and cost control. At the same time, the financial risk remains manageable. Future production could provide the funds needed to finance drilling programs and resource expansions more independently.

Furthermore, launching production could position the company as an attractive takeover target. With a resource of approximately 1.2 million ounces of gold, the SMSZ project already has the critical size to be attractive to gold companies. And there is no shortage of gold companies in the region. Allied Gold, Endeavour Mining, Barrick Mining, and B2Gold are active in the vicinity. Incidentally, the SMSZ resource is open in all directions. An upward revision is therefore certainly on the cards.

Against the backdrop of the start of production, GBC Research recommends buying Desert Gold shares. The price target is CAD 0.93. The stock is currently trading at around CAD 0.12. From the analysts’ perspective, the upside potential is therefore significant. The company is currently valued at less than CAD 50 million. Analysts value the Barani East project alone at USD 89.6 million. Overall, they estimate Desert Gold’s intrinsic value at USD 244.8 million.

https://youtu.be/MK7Gjlfn0jg?si=TP5wJJQq2lK5tWGz

Alarm Bells at BMW

Alarm bells are ringing at BMW. Over the past four weeks, the stock has lost about 20% of its value. Most recently, an earnings warning triggered a sell-off of over 10%. The company expects a sharper decline in pre-tax profit this year than previously anticipated. The return on investment in the automotive business is also expected to be significantly lower, ranging between just 1% and 3%. Previously, the range was between 4% and 6%. The main factors weighing on the company are a difficult market environment in China, intense price pressure, additional costs stemming from the tense situation in the Middle East, and accelerated cost-cutting measures within the group.

Analysts have now also reacted to the disaster. Yesterday, Bernstein Research lowered its price target for BMW shares from EUR 108 to EUR 85. Estimates for the current and coming years were reduced. At least the “Outperform” recommendation remained in place, as the stock is currently trading at around EUR 60.

UBS and Berenberg take a more critical view of the German premium automaker’s stock. UBS lowered its price target from EUR 88 to EUR 70. Berenberg estimates the fair value of BMW shares at EUR 69.

Sell-off at BioNTech

Is a sell-off beginning at BioNTech? “Reuters” reports that Moderna is exploring investments in German production capacity. The US biotech company is eyeing the sites that BioNTech plans to close as part of its restructuring. Moderna CEO Stéphane Bancel made it clear that an acquisition or partnership could offer advantages over building a facility from scratch. This would require reaching a suitable agreement with the German government. The company is likely speculating on subsidies or tax breaks.

For BioNTech, selling the facilities would make sense in principle. Following the end of the pandemic boom, the Mainz-based company is scaling back its production capacity focused on COVID-19 vaccines and intends to concentrate more heavily on developing new cancer immunotherapies and other pipeline projects. In May, BioNTech announced it would close several sites in Germany and Singapore. This could affect up to 1,860 jobs. At the same time, the company plans to repurchase up to USD 1 billion in its own shares.

BioNTech faced significant criticism for these plans, particularly from politicians. The main concern is that, following the experiences of the pandemic, Germany could lose important vaccine production capacity and, in the event of a crisis, once again become dependent on foreign supply chains. Furthermore, questions are being raised as to whether a company that benefited significantly from public support and government trust during the pandemic should now be cutting production sites and jobs so drastically. BioNTech, on the other hand, points to excess capacity for COVID-19 vaccines and its strategic focus on oncology.

The transaction could be positive for all parties. BioNTech could monetize unused capacity and limit the damage to its reputation. Moderna could gain production capacity more quickly. And jobs would be preserved.

In recent weeks, BioNTech’s share has been trading sideways without much momentum around EUR 80.

BioNTech’s strategy is, in any case, a warning sign for Germany as a business location. Buying shares in Germany’s largest biotech company is not compelling at present. In contrast, Desert Gold’s attractive valuation makes it an appealing entry point. The GBC study impressively demonstrates that the intrinsic value is significantly higher than the current share price. BMW is currently introducing numerous new electric models. Their success is likely to have a strong influence on the stock’s performance.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.